Why Is REVOLUTION MEDICINES (RVMD) Stock Down Today?

Revolution Medicines (RVMD) shares fell 7.72% to close at $185.37 on October 8, 2026. The primary driver for the decline was the release of preclinical data by Propanc Biopharma, which reported a 90% tumor growth inhibition rate in pancreatic cancer models using its drug PRP. This result presented a contrasting profile to Revolution Medicines’ lead candidate, daraxonrasib, prompting a reassessment of the competitive landscape for RAS-targeted therapies.

What Happened

Propanc Biopharma disclosed new data on October 7 showing significant efficacy in pancreatic cancer models. The announcement highlighted a distinct mechanism of action compared to Revolution Medicines’ daraxonrasib, leading to immediate market reaction. While the company continues to advance its clinical pipeline, including the RASolute 309 Phase 3 trial evaluating the combination of RASONQUE and zoldonrasib for first-line treatment in metastatic RAS G12D pancreatic ductal adenocarcinoma, the new competitor data weighed on sentiment.

Analyst activity remained positive despite the price drop. RBC Capital raised its price target to $259 from $251, while Truist Securities increased its target to $240 from $239. Both firms maintained Buy ratings. Other recent coverage included Brookline Capital initiating coverage with a Buy rating and a $318 price target, and Goldman Sachs reinstating a Buy rating with a $267 target. However, these bullish assessments did not prevent the stock from trading lower in the session.

What The Data Shows

The stock opened at $200.15, which was also the session high at 7:20 AM ET. It declined steadily to a session low of $185.00 at 10:00 AM ET, closing near that level at $185.37. Trading volume was 0.4 million shares, which is 0.2 times the three-month daily average, indicating a thin session. The company has a market capitalization of $42.8 billion and remains unprofitable with a trailing twelve-month EPS of -$8.92. Revenue declined 97.2% over the same period. The stock’s beta is 1.40, and it trades within a 52-week range of $45.80 to $224.31.

Insider activity shows significant selling pressure. Over the last 90 days, there have been 18 sales totaling $78.0 million, with no purchases. Recent filings include sales by Chief Development Officer Alan B. Sandler on September 29, SVP and General Counsel Jeff Cislini on September 25, and Anthony Mancini on September 24. Congressional disclosures show two purchases by Donald J. Trump in June and July 2026, each in the $1,001 to $15,000 range. The 52-week tape recorded one fresh high and 18 fresh lows on October 8.

What To Watch

Investors will monitor the progress of the RASolute 309 Phase 3 trial, which is currently enrolling patients. The market will also observe how the competitive data from Propanc Biopharma influences long-term valuation models for Revolution Medicines’ RAS inhibitor portfolio.